{"altmetric_id":1633321,"counts":{"readers":{"mendeley":24,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":2,"unique_users":[53497,384],"posts_count":3},"total":{"posts_count":3}},"citation":{"abstract":"Patients with progressive or recurrent supratentorial high-grade gliomas were entered into a multicentre phase II trial to evaluate the efficacy and toxicity of temozolomide.","abstract_source":"pubmed","altmetric_jid":"4f6fa4e93cf058f610002497","authors":["Bower, M","Newlands, E S","Bleehen, N M","Brada, M","Begent, R J","Calvert, H","Colquhoun, I","Lewis, P","Brampton, M H"],"doi":"10.1007\/s002800050691","first_seen_on":"2013-07-18T16:03:02+00:00","issns":["0344-5704"],"issue":"6","journal":"Cancer Chemotherapy & Pharmacology","last_mentioned_on":1374156300,"links":["http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9332462"],"pmid":"9332462","pubdate":"1997-01-01T00:00:00+00:00","publisher":"SPRINGER VERLAG","publisher_subjects":[{"name":"Pharmacology And Pharmaceutical Sciences","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Pharmacology, Toxicology and Pharmaceutics","Biochemistry, Genetics and Molecular Biology"],"subjects":["neoplasms","antineoplasticagents"],"title":"Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.","type":"article","volume":"40","mendeley_url":"http:\/\/www.mendeley.com\/research\/multicentre-crc-phase-ii-trial-temozolomide-recurrent-progressive-highgrade-glioma"},"altmetric_score":{"score":13.608,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":13.608},"context_for_score":{"all":{"total_number_of_other_articles":4011094,"mean":5.0321032720621,"rank":230332,"this_scored_higher_than_pct":94,"this_scored_higher_than":3780571,"rank_type":"exact","sample_size":4011094,"percentile":94},"similar_age_3m":{"total_number_of_other_articles":87719,"mean":7.4342340025309,"rank":7860,"this_scored_higher_than_pct":91,"this_scored_higher_than":79856,"rank_type":"exact","sample_size":87719,"percentile":91},"this_journal":{"total_number_of_other_articles":394,"mean":2.1672162849873,"rank":5,"this_scored_higher_than_pct":98,"this_scored_higher_than":389,"rank_type":"exact","sample_size":394,"percentile":98},"similar_age_this_journal_3m":{"total_number_of_other_articles":9,"mean":1.075,"rank":1,"this_scored_higher_than_pct":88,"this_scored_higher_than":8,"rank_type":"exact","sample_size":9,"percentile":88}}},"demographics":{"users":{"mendeley":{"by_status":{"Professor > Associate Professor":2,"Researcher":5,"Student  > Ph. D. Student":5,"Student  > Postgraduate":1,"Other":5,"Student  > Master":1,"Student  > Bachelor":3,"Lecturer > Senior Lecturer":1,"Professor":1},"by_discipline":{"Medicine and Dentistry":10,"Chemistry":3,"Agricultural and Biological Sciences":8,"Biochemistry, Genetics and Molecular Biology":2,"Pharmacology, Toxicology and Pharmaceutical Science":1}}},"geo":{"mendeley":{"BR":1,"GB":2}}},"posts":{"blogs":[{"title":"The story of temozolomide","url":"http:\/\/scienceblog.cancerresearchuk.org\/2013\/07\/18\/the-story-of-temozolomide\/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+cancerresearchuk%2FSHhE+%28Cancer+Research+UK+-+Science+Update%29","citation_ids":[1633317,1633318,1633319,1633320,1633321,1633322],"posted_on":"2013-07-18T14:05:00+00:00","summary":"This entry is part 13 of 13 in our High-impact science series Parminder had temozolomide for her brain tumour &#8211; a drug our scientists developed.\nThe development of the brain tumour drug temozolomide(also known as Temodar, Temodal and Temcad) is a shi","author":{"name":"Cancer Research UK - Science Update blog","url":"http:\/\/scienceblog.cancerresearchuk.org","description":"The latest news, views and opinions from Cancer Research UK"}},{"title":"The story of temozolomide","url":"http:\/\/scienceblog.cancerresearchuk.org\/2013\/07\/18\/the-story-of-temozolomide\/","citation_ids":[1633317,1633318,1633319,1633320,1633321,1633322],"posted_on":"2013-07-18T14:05:00+00:00","summary":"This entry is part 12 of 13 in our High-impact science series Parminder had temozolomide for her brain tumour &#8211; a drug our scientists developed.\nThe development of the brain tumour drug temozolomide(also known as Temodar, Temodal and Temcad) is a shi","author":{"name":"Cancer Research UK - Science Update","url":"http:\/\/scienceblog.cancerresearchuk.org\/","description":"The latest news, views and opinions from Cancer Research UK"}},{"title":"The story of temozolomide","url":"https:\/\/scienceblog.cancerresearchuk.org\/2013\/07\/18\/the-story-of-temozolomide\/?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+cancerresearchuk%2FSHhE+%28Cancer+Research+UK+-+Science+Update%29","citation_ids":[1633317,1633318,1633319,1633320,1633321,1633322],"posted_on":"2013-07-18T14:05:00+00:00","summary":"This entry is part 13 of 13 in our High-impact science series Parminder had temozolomide for her brain tumour &#8211; a drug our scientists developed.\nThe development of the brain tumour drug temozolomide(also known as Temodar, Temodal and Temcad) is a shi","author":{"name":"Cancer Research UK - Science Update","url":"http:\/\/scienceblog.cancerresearchuk.org\/","description":"The latest news, views and opinions from Cancer Research UK"}}]}}